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SUMM A R Y
Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effec-
tive in treating tumors harboring alterations in the mTOR pathway. Mechanisms of 
resistance to everolimus remain undefined. Resistance developed in a patient with 
metastatic anaplastic thyroid carcinoma after an extraordinary 18-month response. 
Whole-exome sequencing of pretreatment and drug-resistant tumors revealed a 
nonsense mutation in TSC2, a negative regulator of mTOR, suggesting a mechanism 
for exquisite sensitivity to everolimus. The resistant tumor also harbored a muta-
tion in MTOR that confers resistance to allosteric mTOR inhibition. The mutation 
remains sensitive to mTOR kinase inhibitors.
A better understanding of the mechanisms of sensitivity and re-sistance to anticancer therapies may improve patient selection and allow the development of rational treatment designs. One approach involves studying 
paired biopsy samples of pretreatment and drug-resistant tumors obtained from pa-
tients with exquisite sensitivity or unusually durable responses to therapy.
Everolimus is a Food and Drug Administration–approved oral allosteric inhibitor of 
mTOR. Tumors that exhibit a dependency on the mTOR pathway might have enhanced 
sensitivity to mTOR inhibition. Inactivating mutations in the tumor-suppressor genes 
TSC1, TSC2, and STK11 result in mTOR-pathway activation and are target able by TOR 
inhibitors in hamartoma syndromes1-3 and in malignant perivascular epithelioid-cell 
tumors.4 In a phase 2 study of everolimus in urothelial carcinoma, whole-genome 
sequencing in a patient who had a durable complete remission revealed a somatic TSC1 
mutation.5 We recently identified an additional mechanism of exquisite sensitivity to 
everolimus in a patient with metastatic urothelial carcinoma: activating mutations in 
mTOR itself.6 Although mechanisms of sensitivity to everolimus are beginning to be 
identified, mechanisms of clinically acquired resistance to everolimus remain unknown.
We identified a patient with metastatic anaplastic thyroid cancer, an aggressive 
neoplasm associated with a median survival of 5 months, who had exquisite sen-
sitivity to everolimus. The patient, who was enrolled in a phase 2 study of everolimus 
for thyroid cancer (ClinicalTrials.gov number, NCT00936858), had a near-complete 
response that lasted for 18 months, followed by progressive disease. Of seven 
patients with anaplastic thyroid cancer treated with everolimus in this trial to date, 
this patient was the only one who had a response. To identify potential genomic 
mechanisms of exquisite sensitivity and acquired resistance to everolimus, we 
performed whole-exome sequencing on the pretreatment and drug-resistant tumors.
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C A SE R EPORT
The patient is a 57-year-old woman who had not-
ed a rapidly enlarging mass on the left side of her 
neck in 2010. She underwent a total thyroidecto-
my and central neck dissection, which revealed a 
3.8-cm anaplastic thyroid cancer arising in a 
background of an oncocytic variant of poorly dif-
ferentiated thyroid cancer (Fig. 1A, and Fig. S1 in 
Supplementary Appendix 1, available with the 
C
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Figure 1. Histologic Findings and Computed Tomographic (CT) Scans in a Patient with Metastatic Anaplastic Thyroid 
Carcinoma.
Hematoxylin and eosin staining of a total-thyroidectomy specimen (Panel A, top) shows anaplastic thyroid carci-
noma; MIB-1 staining (Panel A, bottom) reveals the high proliferative rate of the tumor. A histologic section (hema-
toxylin and eosin) of an enlarged mediastinal lymph node, obtained after 18 months of a response to everolimus 
monotherapy, shows recurrent thyroid carcinoma (Panel B). Axial CT scans of the chest show a right-sided hilar 
mass (arrow) before treatment with everolimus (Panel C), 6 months after treatment initiation (Panel D), and at the 
time of everolimus resistance, 18 months after treatment initiation (Panel E).
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full text of this article at NEJM.org). Resection 
margins were positive, and 3 of 12 lymph nodes 
were involved. At 3 weeks after surgery, the serum 
thyroglobulin level was 17.2 ng per milliliter, with 
undetectable thyroglobulin antibodies.
The patient received concurrent radiation ther-
apy and weekly carboplatin and paclitaxel chemo-
therapy. The serum thyroglobulin level at 4 weeks 
after the completion of chemotherapy and radia-
tion therapy was 12.0 ng per milliliter. Restaging 
scans obtained 3 months later revealed a new, 
right-sided hilar mass (Fig. 1C), and the patient 
enrolled in a phase 2 clinical trial of everolimus, 
which was administered at a dose of 10 mg daily. 
Within 6 months, follow-up scans showed that the 
lesion had greatly diminished in size (from 3.0 by 
2.6 cm to 1.1 by 0.8 cm) (Fig. 1D).
After 18 months of a sustained response to 
everolimus, scans revealed progressive disease 
(Fig. 1E). The patient underwent a mediastinoscopy 
with removal of an enlarged lymph node, which 
contained metastatic anaplastic thyroid cancer 
(Fig. 1B, and Fig. S1 in Supplementary Appendix 
1). Whole-exome sequencing was performed on 
biopsy samples of the pretreatment and resistant 
tumors as well as on a blood sample.
Me thods
Oversight
The study was approved by the institutional review 
board of the Dana–Farber/Harvard Cancer Center. 
The patient provided written informed consent for 
sequencing.
Histologic Studies
Tumor sections were deparaffinized and stained 
with antibodies against pS6 (phosphorylated ribo-
somal protein S6) and TSC2 with the use of stan-
dard protocols. For details, see the Methods section 
in Supplementary Appendix 1.
Whole-Exome Sequencing
Whole-exome sequencing was performed on the 
pretreatment tumor, the resistant tumor, and 
blood. The mean depth of coverage for the pre-
treatment and resistant tumors was 300× and 375×, 
respectively. Somatic point mutations, small in-
sertions or deletions (indels), and copy-number 
alterations, detected in the tumor DNA but not 
the germline DNA, were identified (Table S1 in 
Supplementary Appendix 2 [described in Supple-
mentary Appendix 1]). Evaluation for rearrange-
ments was not performed.
laboratory studies
Expression plasmids containing mTOR comple-
mentary DNA (cDNA) were generated, and site-
directed mutagenesis, stable transfections, analysis 
of cell-growth inhibition, and immunoblot stud-
ies were performed. For details, see the Methods 
section in Supplementary Appendix 1.
R esult s
Mutations in TSC2 and MTOR
The pretreatment tumor contained a somatic non-
sense mutation in the tumor-suppressor gene 
TSC2 that inactivates the gene, allowing for acti-
vation of the mTOR pathway7,8 and resulting in 
sensitivity to mTOR inhibition in some cancers1,2,4,9 
Figure 2 (facing page). Mutations in TSC2 and MTOR 
in Anaplastic Thyroid Carcinoma Revealed by Whole-
Exome Sequencing.
Whole-exome sequencing of the tumor tissue before 
treatment and after the development of resistance to 
everolimus revealed a TSC2 nonsense mutation in both 
tumors (Panel A) and an F2108L mutation in MTOR in 
the resistant tumor that was undetectable in the pre-
treatment tumor (Panel B). Representative genome im-
ages from the Integra tive Genomics Viewer (Broad 
Institute), along with the number of reads for the refer-
ence allele and the variant allele, are shown for each 
alteration. A comparison of the proportion of cancer 
cells harboring specific mutations in the pretreatment 
biopsy sample (Panel C, x axis) versus those in the 
post-resistance biopsy sample (y axis) is shown. Muta-
tions in TSC2, TP53, and FLCN were present in all can-
cer cells from both biopsy samples (yellow triangle at 
upper right), whereas the MTOR mutation was detected 
in all cancer cells in the post-resistance biopsy sample 
but was not detected in the pretreatment biopsy sam-
ple (red triangle at upper left). Additional mutations 
were detected in all cancer cells in the pretreatment 
biopsy sample but in no cancer cells in the post-resis-
tance biopsy sample (light blue triangle at lower right). 
Other mutations were predicted to occur in a sub-
group of the cancer cells in the pretreatment biopsy 
but in none of the cancer cells in the post-resistance 
biopsy sample (dark blue) or in a subgroup of the can-
cer cells in the post-resistance biopsy sample but in 
none of the cancer cells in the pretreatment biopsy 
sample (dark red). Shaded areas denote Bayesian pos-
terior probability distributions over cancer-cell fraction 
values for each mutation. Gray shading indicates mu-
tations with cancer-cell fraction distributions having 
considerable uncertainty, with lighter shading indicat-
ing greater uncertainty.
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(Fig. 2A). This truncating mutation (Q1178*) is 
known to inactivate TSC2 by eliminating the gua-
nosine triphosphatase–activating protein domain 
near the C-terminal, a domain essential for inhib-
iting mTOR complex 1.8,10 Somatic mutations in 
TSC2 have been identified in many tumor types, 
including cancers of the kidney and bladder as 
well as hamartomas and malignant perivascular 
epithelioid-cell tumors in patients with tuberous 
sclerosis complex. TSC2 mutations have not previ-
ously been reported in any type of thyroid cancer. 
TSC2 Q1178* has been identified twice in the 
germline of patients with tuberous sclerosis 
complex,11 but somatic mutations at this locus 
have not been reported.
In addition to the TSC2 mutation, 317 somatic 
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coding single-nucleotide variants and 44 coding 
indels were identified (Table S1 in Supplementary 
Appendix 2). These included a common mutation 
in TP53 (C135Y) and an N-terminal frame shift in 
FLCN (R17fs), a tumor-suppressor gene that en-
codes folliculin. Germline mutations in folliculin 
result in the Birt–Hogg–Dubé syndrome, an auto-
somal dominant disorder characterized by fibro-
folliculomas, renal and pulmonary cysts, and re-
nal cancer. Folliculin is involved in TSC2 and 
mTOR signaling12-15; in some studies, inactivation 
of FLCN has been shown to result in increased 
mTOR activity,14 raising the possibility that this 
mutation, along with the TSC2 mutation, may con-
tribute to sensitivity to everolimus.
Genomewide copy-number analysis showed 
near-haploidization of the cancer genome with 
retention of chromosome 7, a feature that appears 
to be pathognomonic of oncocytic follicular thy-
roid carcinoma,16 This finding is consistent with 
the putative origin of this anaplastic thyroid can-
cer (Fig. S2 in Supplementary Appendix 1).
The TSC2 nonsense mutation persisted in the 
resistant tumor (Fig. 2A). Immunohistochemical 
analysis of tissue from the resistant tumor re-
vealed the absence of TSC2 and the presence of 
pS6, a downstream target of mTOR. These find-
ings are indicative of persistent mTOR-pathway 
activity (Fig. S3 in Supplementary Appendix 1). 
Immunohistochemical analysis of the pretreat-
ment tissue could not be completed for technical 
reasons. Mutations in TP53 and FLCN also per-
sisted in the resistant tumor.
The resistant tumor also had a somatic muta-
tion in MTOR (MTORF2108L). This mutation was 
not detected in the pretreatment tumor despite 
robust sequence coverage of this locus (189×) 
(Fig. 2B). To identify the relative change in the 
frequency of each genomic alteration from the 
pretreatment tumor to the resistant tumor, the 
fraction of tumor cells harboring a given alteration 
in each pair of samples was estimated (Fig. 2C, 
and Table S1 in Supplementary Appendix 2). 
Although the TSC2, TP53, and FLCN alterations 
were estimated to be present in 98 to 100% of 
the cancer cells in both the pretreatment and re-
sistant tumors, the estimated proportion of cancer 
cells with MTORF2108L was 0% in the pretreatment 
tumor as compared with 96% in the resistant 
tumor (Fig. 2C). To our knowledge, MTOR muta-
tions have not previously been identified in pa-
tients with acquired resistance to everolimus, and 
this particular mutation has not been described 
in patients.17
Resistance to Allosteric mTOR Inhibitors 
Resulting from mTORF2108L
Although MTORF2108L has not been described pre-
viously, the homologous mutation was character-
ized nearly 20 years ago in fission yeast.18 In a 
mutagenesis screen to identify mutations in tor2 
(the fission yeast homologue of MTOR) that con-
ferred resistance to rapamycin, tor2F2049L was one 
of five rapamycin-resistant mutants identified. 
All five tor2 residues identified have been con-
served in TOR proteins across species, including 
mTOR.18 In a yeast two-hybrid assay, tor2F2049L 
did not bind FKBP (FK506 binding protein)–ra-
pamycin, suggesting a mechanism for rapamycin 
resistance in fission yeast.18
On the basis of these findings, we hypothesized 
that mTORF2108L causes resistance to allosteric 
mTOR inhibition by preventing the binding of the 
drug to the protein. Indeed, structural studies con-
firm that mTORF2108L occurs in the FKBP–rapamy-
cin binding (FRB) domain, the region of the pro-
tein that is required to bind to rapamycin and its 
analogues. As shown in Figures 3A and 3B, the 
substitution of a leucine for a phenylalanine is 
predicted to prevent binding of the drug to the 
protein by means of steric hindrance.
Figure 3 (facing page). Effects of Nonmutant mTOR 
and mTORF2108L.
Ribbon rendition of mTOR crystal structure (PDB 
1FAP) for nonmutant mTOR (Panel A) and mTORF2108L 
(Panel B) shows the FKBP (FK506 binding protein)– 
rapamycin binding (FRB) domain, FKBP12, and rapa-
mycin. Enlarged views show that the substitution of 
leucine for phenylalanine sterically hinders rapamycin 
binding (Panels A and B, right side). Ribbon rendition 
of mTOR crystal structure (PDB 4JSX) (Panel C) high-
lights the kinase domain (KD) C-terminal lobe, KD 
N-terminal lobe, FRB domain, and FAT domain. As 
shown, residue F2108 is not expected to be involved 
with binding of torin 2. Growth-inhibition curves are 
shown for rapamycin (Panel D) and torin 1 (Panel E) 
in human embryonic kidney (HEK) 293T cells stably 
expressing nonmutant mTOR or MTORF2108L. Con-
structs expressing mTORF2108L or nonmutant mTOR 
were expressed in HEK 293T cells (Panel F). The levels 
of phosphorylated and total S6 kinase 1 (S6K1), the 
downstream target of mTOR, are shown for the HEK 
293T cells after treatment with 0 nM, 0.5 nM, 2.5 nM, 
or 12.5 nM of rapamycin or torin 1, as indicated. 
GAPDH denotes glyceraldehyde 3-phosphate dehy-
drogenase.
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To confirm that mTORF2108L confers resistance 
to allosteric mTOR inhibition, the F2108L muta-
tion was introduced into nonmutant mTOR, and 
the mutant cDNA was stably expressed in human 
embryonic kidney (HEK) 293T cells. Cells express-
ing mTORF2108L were significantly more resistant 
to inhibition with rapamycin than were cells ex-
pressing nonmutant mTOR (Fig. 3D). We next ex-
amined the effect of the mutant on the phos-
phorylation of endogenous S6 kinase 1 (S6K1), a 
downstream target of mTOR. At baseline, cells 
expressing mTORF2108L and those expressing non-
mutant mTOR had similar levels of phosphorylated 
S6K1. Treatment with rapamycin, however, com-
pletely inhibited phosphorylation of S6K1 in cells 
expressing nonmutant mTOR but had virtually no 
effect in cells expressing mTORF2108L (Fig. 3F).
Sensitivity of mTORF2108L to Direct TOR Kinase 
Inhibition
Because mTORF2108L occurs in the FRB domain 
rather than the active site, we hypothesized that 
this mutant protein should remain sensitive to 
inhibition by direct ATP-competitive TOR kinase 
inhibitors. As shown in the structural model in 
Figure 3C, there is no predicted effect of the 
F2108L mutation on binding of torin 1, a direct 
TOR inhibitor. In contrast to cells treated with 
rapamycin, cells expressing mTORF2108L and those 
expressing nonmutant mTOR were equally sensi-
tive to treatment with torin 1 (Fig. 3E). Similarly, 
inhibition of S6K1 phosphorylation by torin 1 
was equivalent in cells expressing mTORF2108L 
and those expressing nonmutant mTOR (Fig. 3F). 
Taken together, these results indicate that 
mTORF2108L remains sensitive to direct kinase 
inhibition.
Discussion
This report of a nonsense mutation in TSC2 in a 
tumor from a patient with anaplastic thyroid can-
cer who had a response to everolimus supports 
the notion that cancers of diverse types with mTOR-
pathway–activating mutations are sensitive to 
mTOR inhibitors.1-6 Once resistance emerged in 
this patient, the mechanism of acquired resistance 
to everolimus was identified as a mutation in 
mTOR that prevented everolimus from binding 
to mTOR. The mutant mTOR remained sensitive 
to direct mTOR kinase inhibition.
Anaplastic thyroid cancer is a highly aggres-
sive and rapidly fatal disease, for which there is 
no adequate treatment. To date, limited molecu-
lar profiling studies in this disease have identi-
fied a few targetable alterations. Oncogenic BRAF 
mutations have been described, and a response 
to the RAF inhibitor vemurafenib was observed 
in a patient with BRAF-mutant anaplastic thyroid 
cancer.19 Additional targetable alterations include 
mutations in PIK3CA, PTEN, KRAS, NRAS, and 
ALK.20,21 Genomic profiling of anaplastic thyroid 
cancer to screen for mTOR-pathway alterations 
may identify subgroups of patients who are po-
tential candidates for enrollment in clinical trials 
of mTOR-directed therapies. Indeed, several 
activating alterations in the mTOR pathway — 
including alterations in MTOR, TSC1 or TSC2, 
STK11, and RHEB — have been observed recur-
rently in multiple cancer types,5,6,17 providing the 
rationale for the development of so-called basket 
trials of mTOR inhibitors in patients with di-
verse tumor types who have somatic mTOR-
pathway alterations.
Although cancers driven by a dominant onco-
gene frequently have dramatic responses to tar-
geted kinase inhibitors, the tumors invariably be-
come resistant to these agents. The majority of 
known mechanisms of clinical resistance involve 
secondary mutations in the target kinase. Such 
mutations has been described for ABL, KIT, EGFR, 
ALK, BRAF, MEK, PDGFRA, FLT3, and ROS1.22-24 
Indeed, in the case of every kinase inhibitor for 
which a resistance mechanism has been described, 
there is clinical evidence that resistance can oc-
cur through a secondary alteration in the target 
kinase. Our results indicate that acquired resis-
tance to mTOR inhibition can occur through the 
same mechanism. It is likely that additional sec-
ondary mutations in the mTOR FRB domain will 
be identified in patients, as suggested by studies 
in fission yeast18 and experience with other tu-
mor types.23,24 We speculate that these patients 
would be ideal candidates for clinical trials of 
mTOR kinase inhibitors.
Serial biopsies to profile tumors that develop 
resistance to targeted therapies have the poten-
tial not only to uncover mechanisms of thera-
peutic resistance but also to suggest effective 
follow-up treatment. Ultimately, a comprehensive 
knowledge of mechanisms of acquired resistance, 
coupled with the ability to diagnose the relevant 
mechanisms in situ, may lead to the development 
of therapeutic strategies, including targeted com-
binations, that are capable of producing long-
term responses in many cancers.
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